The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Immunoglobulin G Antibody Therapeutics Market Research Report 2024

Global Immunoglobulin G Antibody Therapeutics Market Research Report 2024

Publishing Date : Jan, 2024

License Type :
 

Report Code : 1897145

No of Pages : 89

Ask Your Query

Synopsis

Antibody, also called immunoglobulin, a protective protein produced by the immune system in response to the presence of a foreign substance, called an antigen. Antibodies recognize and latch onto antigens in order to remove them from the body. A wide range of substances are regarded by the body as antigens, including disease-causing organisms and toxic materials such as insect venom.

Treatment that uses antibodies to help the body fight cancer, infection, or other diseases. Antibodies are proteins made by the immune system that bind to specific markers on cells or tissues. IgG1 antibodies are a type of antibody made in the laboratory that can be used in diagnosis or treatment. In cancer treatment, IgG1 antibodies may kill cancer cells directly, they may block development of tumor blood vessels, or they may help the immune system kill cancer cells.

The global Immunoglobulin G Antibody Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs.

However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Immunoglobulin G Antibody Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Immunoglobulin G Antibody Therapeutics.

Report Scope

The Immunoglobulin G Antibody Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Immunoglobulin G Antibody Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Immunoglobulin G Antibody Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

By Company

  • Roche
  • Abbvie
  • J & J
  • Bristol-Myers Squibb
  • Novartis
  • Merck
  • Alexion Pharmaceuticals
  • Takeda
  • Amgen
  • Biogen
  • UCB
  • Eli Lilly and Company
  • AstraZeneca

Segment by Type

  • IgG1
  • IgG4
  • Others

Segment by Application

  • Autoimmune
  • Tumor
  • Others

By Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Netherlands)
  • Asia-Pacific (China, Japan, South Korea, China Taiwan, Southeast Asia, India)
  • Latin America, Middle East & Africa (Latin America, Mexico, Brazil, Turkey)

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Immunoglobulin G Antibody Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Immunoglobulin G Antibody Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 IgG1
1.2.3 IgG4
1.2.4 Others
1.3 Market by Application
1.3.1 Global Immunoglobulin G Antibody Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Autoimmune
1.3.3 Tumor
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Immunoglobulin G Antibody Therapeutics Market Perspective (2019-2030)
2.2 Immunoglobulin G Antibody Therapeutics Growth Trends by Region
2.2.1 Global Immunoglobulin G Antibody Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Immunoglobulin G Antibody Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Immunoglobulin G Antibody Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Immunoglobulin G Antibody Therapeutics Market Dynamics
2.3.1 Immunoglobulin G Antibody Therapeutics Industry Trends
2.3.2 Immunoglobulin G Antibody Therapeutics Market Drivers
2.3.3 Immunoglobulin G Antibody Therapeutics Market Challenges
2.3.4 Immunoglobulin G Antibody Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Immunoglobulin G Antibody Therapeutics Players by Revenue
3.1.1 Global Top Immunoglobulin G Antibody Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Immunoglobulin G Antibody Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Immunoglobulin G Antibody Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Immunoglobulin G Antibody Therapeutics Revenue
3.4 Global Immunoglobulin G Antibody Therapeutics Market Concentration Ratio
3.4.1 Global Immunoglobulin G Antibody Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Immunoglobulin G Antibody Therapeutics Revenue in 2023
3.5 Immunoglobulin G Antibody Therapeutics Key Players Head office and Area Served
3.6 Key Players Immunoglobulin G Antibody Therapeutics Product Solution and Service
3.7 Date of Enter into Immunoglobulin G Antibody Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Immunoglobulin G Antibody Therapeutics Breakdown Data by Type
4.1 Global Immunoglobulin G Antibody Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Immunoglobulin G Antibody Therapeutics Forecasted Market Size by Type (2025-2030)
5 Immunoglobulin G Antibody Therapeutics Breakdown Data by Application
5.1 Global Immunoglobulin G Antibody Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Immunoglobulin G Antibody Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Immunoglobulin G Antibody Therapeutics Market Size (2019-2030)
6.2 North America Immunoglobulin G Antibody Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Immunoglobulin G Antibody Therapeutics Market Size by Country (2019-2024)
6.4 North America Immunoglobulin G Antibody Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Immunoglobulin G Antibody Therapeutics Market Size (2019-2030)
7.2 Europe Immunoglobulin G Antibody Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Immunoglobulin G Antibody Therapeutics Market Size by Country (2019-2024)
7.4 Europe Immunoglobulin G Antibody Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Immunoglobulin G Antibody Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Immunoglobulin G Antibody Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Immunoglobulin G Antibody Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Immunoglobulin G Antibody Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Immunoglobulin G Antibody Therapeutics Market Size (2019-2030)
9.2 Latin America Immunoglobulin G Antibody Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Immunoglobulin G Antibody Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Immunoglobulin G Antibody Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Immunoglobulin G Antibody Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Immunoglobulin G Antibody Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Immunoglobulin G Antibody Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Immunoglobulin G Antibody Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Immunoglobulin G Antibody Therapeutics Introduction
11.1.4 Roche Revenue in Immunoglobulin G Antibody Therapeutics Business (2019-2024)
11.1.5 Roche Recent Development
11.2 Abbvie
11.2.1 Abbvie Company Detail
11.2.2 Abbvie Business Overview
11.2.3 Abbvie Immunoglobulin G Antibody Therapeutics Introduction
11.2.4 Abbvie Revenue in Immunoglobulin G Antibody Therapeutics Business (2019-2024)
11.2.5 Abbvie Recent Development
11.3 J & J
11.3.1 J & J Company Detail
11.3.2 J & J Business Overview
11.3.3 J & J Immunoglobulin G Antibody Therapeutics Introduction
11.3.4 J & J Revenue in Immunoglobulin G Antibody Therapeutics Business (2019-2024)
11.3.5 J & J Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Detail
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Immunoglobulin G Antibody Therapeutics Introduction
11.4.4 Bristol-Myers Squibb Revenue in Immunoglobulin G Antibody Therapeutics Business (2019-2024)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Novartis
11.5.1 Novartis Company Detail
11.5.2 Novartis Business Overview
11.5.3 Novartis Immunoglobulin G Antibody Therapeutics Introduction
11.5.4 Novartis Revenue in Immunoglobulin G Antibody Therapeutics Business (2019-2024)
11.5.5 Novartis Recent Development
11.6 Merck
11.6.1 Merck Company Detail
11.6.2 Merck Business Overview
11.6.3 Merck Immunoglobulin G Antibody Therapeutics Introduction
11.6.4 Merck Revenue in Immunoglobulin G Antibody Therapeutics Business (2019-2024)
11.6.5 Merck Recent Development
11.7 Alexion Pharmaceuticals
11.7.1 Alexion Pharmaceuticals Company Detail
11.7.2 Alexion Pharmaceuticals Business Overview
11.7.3 Alexion Pharmaceuticals Immunoglobulin G Antibody Therapeutics Introduction
11.7.4 Alexion Pharmaceuticals Revenue in Immunoglobulin G Antibody Therapeutics Business (2019-2024)
11.7.5 Alexion Pharmaceuticals Recent Development
11.8 Takeda
11.8.1 Takeda Company Detail
11.8.2 Takeda Business Overview
11.8.3 Takeda Immunoglobulin G Antibody Therapeutics Introduction
11.8.4 Takeda Revenue in Immunoglobulin G Antibody Therapeutics Business (2019-2024)
11.8.5 Takeda Recent Development
11.9 Amgen
11.9.1 Amgen Company Detail
11.9.2 Amgen Business Overview
11.9.3 Amgen Immunoglobulin G Antibody Therapeutics Introduction
11.9.4 Amgen Revenue in Immunoglobulin G Antibody Therapeutics Business (2019-2024)
11.9.5 Amgen Recent Development
11.10 Biogen
11.10.1 Biogen Company Detail
11.10.2 Biogen Business Overview
11.10.3 Biogen Immunoglobulin G Antibody Therapeutics Introduction
11.10.4 Biogen Revenue in Immunoglobulin G Antibody Therapeutics Business (2019-2024)
11.10.5 Biogen Recent Development
11.11 UCB
11.11.1 UCB Company Detail
11.11.2 UCB Business Overview
11.11.3 UCB Immunoglobulin G Antibody Therapeutics Introduction
11.11.4 UCB Revenue in Immunoglobulin G Antibody Therapeutics Business (2019-2024)
11.11.5 UCB Recent Development
11.12 Eli Lilly and Company
11.12.1 Eli Lilly and Company Company Detail
11.12.2 Eli Lilly and Company Business Overview
11.12.3 Eli Lilly and Company Immunoglobulin G Antibody Therapeutics Introduction
11.12.4 Eli Lilly and Company Revenue in Immunoglobulin G Antibody Therapeutics Business (2019-2024)
11.12.5 Eli Lilly and Company Recent Development
11.13 AstraZeneca
11.13.1 AstraZeneca Company Detail
11.13.2 AstraZeneca Business Overview
11.13.3 AstraZeneca Immunoglobulin G Antibody Therapeutics Introduction
11.13.4 AstraZeneca Revenue in Immunoglobulin G Antibody Therapeutics Business (2019-2024)
11.13.5 AstraZeneca Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock